Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "kidney"

Allopurinol for Gout an Unlikely Contributor to Kidney Disease

Reuters Staff  |  October 8, 2018

NEW YORK (Reuters Health)—Allopurinol does not appear to contribute to decline in kidney function and may actually protect renal function in patients with gout, according to a large population-based study. Gout affects around 4% of Americans and often occurs alongside chronic kidney disease (CKD), Dr. Tuhina Neogi from Boston University School of Medicine and colleagues…

Reduced Serum Uric Acid Levels May Protect Against Renal Function Decline

Lara C. Pullen, PhD  |  April 2, 2018

New research examined the link between a reduction in serum uric acid (SUA) levels and the reduced risk of renal function decline in patients with gout. The findings suggest that aggressive serum acid-lowering approaches may be helpful in slowing the progression of renal disease…

Kateryna Kon / Shutterstock.com

How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

Ruth Jessen Hickman, MD  |  December 17, 2017

Anemia is common in patients with systemic rheumatic disease, yet it may not get the attention it deserves. Anemia can result from chronic inflammation, treatment side effects or other disease factors, or it may signal an unrelated condition. Although diagnosis and treatment of anemia are sometimes challenging, clinicians must do their utmost to rigorously investigate…

Steroids May Increase Infection Risk in Patients with IgA Nephropathy

Lara C. Pullen, PhD  |  September 11, 2017

Treatment with oral methylprednisolone may be associated with an increased risk of serious adverse events, specifically infection, in patients with IgA nephropathy. Despite the five-times higher risk, study results also showed a three-times lower risk of kidney failure for the treatment group…

Voclosporin Promising for Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  June 4, 2017

In a recent clinical trial, voclosporin proved safe and effective at both low and high doses as a treatment for lupus nephritis…

Insufficient Evidence Regarding Osteoporosis Medications in Kidney Patients

Will Boggs, MD  |  April 11, 2017

NEW YORK (Reuters Health)—There are insufficient data to make evidence-based decisions regarding the benefits and harms of osteoporosis medications in patients with chronic kidney disease (CKD), according to a systematic review and meta-analysis. “We found low to moderate evidence for the effects of some but not all of the medications, and the evidence was limited…

New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2016

The FDA is strengthening its warning that canagliflozin and dapagliflozin may increase the risk for acute kidney injury in some patients. Also, the FDA has issued a warning that patients should not exceed recommended doses of loperamide due to increased risks of serious cardiac events…

Figure 1: Hematoxylin & Eosin Staining

Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report

Paul Hoover, MD, PhD, & Lindsey MacFarlane, MD  |  September 15, 2015

A 35-year-old female with a history of systemic lupus erythematosus (SLE) without kidney involvement was admitted to our hospital with low-grade fevers, headache, increasing lower extremity edema and elevated blood pressure. History She was first diagnosed with SLE as a teenager when she developed oral ulcers and pleuritic chest pain and tested positive for anti-Smith…

Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis

Mary Beth Nierengarten  |  September 1, 2014

Rheumatologists urged to monitor signs of kidney dysfunction in patients with RA as higher incidence of reduced kidney function found in these patients

How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

Ruchika Harisingani, MD, Maha Saad, PharmD, CGP, BCPS, Manouchkathe Cassagnol, PharmD, CGP, BCPS  |  October 1, 2013

Narcotic and non-narcotic pain regimens can be used

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences